Financial Statements

Apellis Pharmaceuticals, Inc. (APLS)

$67.85

-0.93 (-1.35%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands , Years are calendar years not fiscal years

Retained Earning Schedule

Year 2022 2021 2020 2019 2018
Retained Earnings (Previous Year) -1,657-926-581-277-
Net Income -652-746-345-310-128
Stock Dividends -16-05-149
Dividend Paid -----
Retained Earnings -2,309-1,657-926-581-277

PPE Schedule

Year 2022 2021 2020 2019 2018
Gross PPE 262516--
Annual Depreciation 031417-
Capital Expenditure -2-1-5-2-
Net PPE 25262516-

Intangible and Goodwill Schedule

Year 2022 2021 2020 2019 2018
Intangible and Goodwill (Previous Year) -----
New Purchases ---879-171-332
Intangible and Goodwill -----

Apellis Pharmaceuticals, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Apellis Pharmaceuticals, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.